Retractable Technologies, Inc. (“Retractable”) (AMEX: RVP), a leading
maker of safety needle devices, announced that a final judgment and
permanent injunction were entered March 4, 2010 in the litigation of
Retractable Technologies, Inc. v. OMI (Occupational & Medical
Innovations Limited, an Australian company).
On December 18, 2009, the jury delivered a verdict in favor of
Retractable in its patent infringement and misappropriation of trade
secrets lawsuit against OMI. The Court ordered that Retractable recover
damages and prejudgment interest from OMI based on OMI’s
misappropriation of trade secrets in the amount of $3,153,575. In
addition, the Court entered a permanent injunction enjoining OMI, its
manufacturers, distributors and service providers from infringing
Retractable’s Patent Number 6,572,584, by making, importing, selling, or
using any of OMI’s syringes in the United States and its territories.
The permanent injunction was effective at 12:00 noon, Central Time, on
March 4, 2010.
Retractable manufactures and markets safety medical products,
principally VanishPoint® automated retraction safety
syringes, automated retraction blood collection devices, and automated
retraction I.V. catheters, that virtually eliminate healthcare worker
exposure to accidental needlestick injuries. These revolutionary devices
use patented technology that causes the contaminated needle to retract
automatically, a feature that is designed to prevent both accidental
needlestick injury and device reuse. Retractable also manufactures and
markets Patient Safe® syringes that are uniquely designed to
reduce the risk of bloodstream infections resulting from catheter hub
contamination. Patient’s Safe unique luer guard reduces the risk of luer
tip contact contamination and the risk of contamination of intravenous
fluid. Retractable's products are distributed by various specialty and
general line distributors.
Utilizing process Raman in optimizing cultivated meat production